{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-004603","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.767905+00:00","generated_at":"2026-05-31T11:25:13.497272+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Celldex Q2 net loss $0.54 per share; Phase 3 CSU program launched","bullets":["Net loss $35.8M ($0.54/share) vs $30.5M loss in Q2 2023; revenue $2.5M, up from $0.3M.","Cash $802.3M as of June 30; sufficient to fund operations through 2027.","Initiated global Phase 3 CSU trials (EMBARQ-CSU1/2) in July 2024; actively enrolling.","Phase 2 CIndU study met primary endpoint (negative provocation test) at Week 12; full data 2H 2024.","Barzolvolimab Phase 2 studies ongoing in PN, EoE; AD study to start YE 2024; bispecific CDX-622 enters clinic in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-004603","json":"https://secwatch.observer/filing/0001171843-24-004603.json","markdown":"https://secwatch.observer/filing/0001171843-24-004603.md","text":"https://secwatch.observer/filing/0001171843-24-004603.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000117184324004603/0001171843-24-004603-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000117184324004603/f8k_080824.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:25:13.497272+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}